Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

InspireMD (Nasdaq: NSPR) Receives FDA PMA Approval for CGuard Prime

InspireMD, Inc. (Nasdaq: NSPR), a medical technology company focused on stroke prevention, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for its CGuard Prime Carotid Stent System. The approval allows the commercial launch of the device in the U.S. …

Team Kalkine | 25 June 2025

argenx (Euronext & Nasdaq: ARGX) Gets EC Approval for VYVGART SC in CIDP Across EU and EEA

argenx SE (Euronext & Nasdaq: ARGX)is a biopharmaceutical company focused on the development of antibody-based treatments for severe autoimmune diseases. Through collaborations with academic researchers, argenx aims to build a portfolio of immune-mediated therapies. The company is advancing its FcRn blocker, efgartigimod, across multiple …

Team Kalkine | 23 June 2025

GH Research (Nasdaq: GHRS) Responds to FDA Hold on GH001 IND, Continues TRD Drug Development

GH Research PLC (Nasdaq: GHRS),a clinical-stage biopharmaceutical company focused on depression treatments, announced that it has submitted its full response to the U.S. Food and Drug Administration (FDA) concerning the clinical hold placed on its Investigational New Drug (IND) application for GH001. The company …

Team Kalkine | 23 June 2025

Roth Capital Reiterates "Buy" Rating on Verona Pharma (NASDAQ: VRNA)

Roth Capital has reaffirmed its "Buy" rating on shares ofVerona Pharma PLC American Depositary Share(NASDAQ: VRNA) while raising its price target to USD116 from the previously assigned USD92. The revised target was noted in a research report issued Wednesday morning, as reported by Benzinga.

Team Kalkine | 19 June 2025

AbbVie (NYSE: ABBV) Reports Positive Phase 3 Results for Atogepant in Migraine Prevention Study

AbbVie, Inc. (NYSE: ABBV)is a U.S.-based biopharmaceutical company headquartered in North Chicago, Illinois. The firm was spun off from Abbott Laboratories in 2013 and focuses on research and development across several therapeutic areas, including immunology, oncology, neuroscience, and eye care. AbbVie markets several major …

Team Kalkine | 19 June 2025

Moleculin Biotech  (NASDAQ: MBRX) Advances Pediatric Annamycin Study After FDA Agreement and Ongoing Phase 3 Trial

Moleculin Biotech, Inc. (NASDAQ: MBRX)is a Houston-based clinical-stage pharmaceutical company focused on the development of oncology therapeutics. Its lead candidates include Annamycin (in development for AML and other cancers), WP1066 (targeting glioblastoma and brain metastases), and other molecules designed to exploit tumor-specific pathways. The …

Team Kalkine | 19 June 2025

Royal Bank of Canada Downgrades Axsome Therapeutics (NASDAQ: AXSM)

Axsome Therapeutics Inc. (NASDAQ: AXSM) experienced a slight drop in its share price this week, following a downgrade by Royal Bank of Canada. The firm adjusted its rating fromOutperformtoMarket Perform, citing a reassessment of valuation metrics and future growth assumptions.

Team Kalkine | 18 June 2025

Genflow Biosciences (LSE:GENF) Advances SIRT6 Pipeline and Aging Trials Across Multiple Programs

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), a UK-based biotechnology company with research operations in Belgium, has provided a mid-year update on its gene therapy pipeline focused on aging and age-related diseases. The company, which holds exclusive rights to SIRT6 gene variants associated with longevity, has reported …

Team Kalkine | 17 June 2025

Amazfit (NYSE: ZEPP) Launches Square Active 2 Smartwatch with Upgraded Health and Fitness Features

Amazfit, the wearable technology brand owned by Zepp Health (NYSE: ZEPP), has launched a new square version of its recently introduced Active 2 smartwatch. Revealed at CES 2025 and also featured at Pepcom and ShowStoppers, the Amazfit Active 2 Square is designed for consumers …

Team Kalkine | 17 June 2025

Goldman Sachs Cuts Price Target on Xenon Pharmaceuticals (NASDAQ:XENE), Maintains 'Buy' Rating

Shares ofXenon Pharmaceuticals Inc. (NASDAQ:XENE)declined by 3.4% during mid-day trading on Monday, reaching an intraday low ofUSD31.57before slightly recovering to close atUSD31.64. The trading volume stood at82,081 shares, sharply lower than the company’s average daily volume of558,820 shares, reflecting an 85% drop.

Team Kalkine | 16 June 2025